...
首页> 外文期刊>Biochemical Pharmacology >Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
【24h】

Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.

机译:脱氧胞苷类似物在人白血病细胞中抑制蛋白激酶C激活剂介导的p21CIP1和p27KIP1诱导:与凋亡和分化的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Events accompanying sequential exposure of U937 leukemic cells to the deoxycytidine (dCyd) analogs 1-[beta-D-arabinofuranosyl]cytosine (ara-C) or 2',2'-difluorodeoxycytidine (gemcitabine; dFdC) followed by two protein kinase C (PKC) activators [bryostatin 1 (BRY) or phorbol 12'-myristate 13'-acetate (PMA)] exhibiting disparate differentiation-inducing abilities were characterized. A 24-hr exposure to 10 nM BRY or PMA after a 6-hr incubation with 1 microM ara-C or 100 nM dFdC resulted in equivalent increases in apoptosis, caspase-3 activation, and polyADP-ribose polymerase degradation, as well as identical DNA cleavage patterns. BRY and PMA did not modify retention of the lethal ara-C metabolite ara-CTP or alter ara-CTP/dCTP ratios. Unexpectedly, pretreatment of cells with ara-C or dFdC opposed BRY- and PMA-related induction of the cyclin-dependent kinase inhibitors (CDKIs) p21CIP1 and/or p27KIP1. These effects were not mimicked by the DNA polymerase inhibitor aphidicolin or by VP-16, a potent inducer of apoptosis. Inhibition of PKC activator-induced CDKI expression by ara-C and dFdC did not lead to redistribution of proliferating cell nuclear antigen but was accompanied by sub-additive or antagonistic effects on leukemic cell differentiation. Sequential exposure of cells to ara-C followed by BRY or PMA led to substantial reductions in clonogenicity that could not be attributed solely to apoptosis. Finally, pretreatment of cells with ara-C attenuated PMA- and BRY-mediated activation of mitogen-activated protein kinase, an enzyme implicated in CDKI induction. Collectively, these findings suggest that pretreatment of leukemic cells with certain dCyd analogs interferes with CDKI induction by the PKC activators PMA and BRY, and that this action may contribute to modulation of apoptosis and differentiation in cells exposed sequentially to these agents.
机译:U937白血病细胞依次暴露于脱氧胞苷(dCyd)类似物1- [β-D-阿拉伯呋喃糖基]胞嘧啶(ara-C)或2',2'-二氟脱氧胞苷(吉西他滨; dFdC),随后是两个蛋白激酶C(表征表现出不同的分化诱导能力的PKC)激活剂[bryostatin 1(BRY)或佛波醇12'-肉豆蔻酸酯13'-乙酸酯(PMA)]。与1 microM ara-C或100 nM dFdC孵育6小时后,暴露于10 nM BRY或PMA 24小时导致细胞凋亡,caspase-3活化和多聚ADP-核糖聚合酶降解的等同增加,并且相同DNA裂解模式。 BRY和PMA不会改变致死性ara-C代谢产物ara-CTP的保留率或改变ara-CTP / dCTP比率。出乎意料的是,用ara-C或dFdC预处理细胞会反对BRY和PMA相关的细胞周期蛋白依赖性激酶抑制剂(CDKI)p21CIP1和/或p27KIP1的诱导。 DNA聚合酶抑制剂aphidicolin或有效的凋亡诱导剂VP-16不能模仿这些作用。 ara-C和dFdC抑制PKC激活剂诱导的CDKI表达不会导致增殖细胞核抗原的重新分布,但伴随着对白血病细胞分化的亚加或拮抗作用。依次将细胞暴露于ara-C之后再进行BRY或PMA导致克隆形成性的大幅降​​低,这不能仅仅归因于细胞凋亡。最后,用ara-C预处理细胞可减弱PMA和BRY介导的促分裂原活化蛋白激酶(一种参与CDKI诱导的酶)的活化。总的来说,这些发现表明用某些dCyd类似物预处理白血病细胞会干扰PKC激活剂PMA和BRY对CDKI的诱导,并且这种作用可能有助于调节顺序暴露于这些试剂的细胞的凋亡和分化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号